Epstein-barr virus latent membrane protein 1 (LMP1) C-terminal-activating region 3 contributes to LMP1-mediated cellular migration via its interaction with Ubc9

Journal of Virology

Volumn 85, Issue 19, 2011, Pages 10144-10153

  Bentz, Gretchen L ^b   Whitehurst, Christopher B ^b   Pagano, Joseph S ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; JANUS KINASE; LATENT MEMBRANE PROTEIN 1; ONCOPROTEIN; PROTEIN UBC9; SUMO PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR; VIRUS PROTEIN;

ARTICLE; C TERMINAL ACTIVATING REGION 1; C TERMINAL ACTIVATING REGION 2; C TERMINAL ACTIVATING REGION 3; CARCINOGENESIS; CELL ACTIVATION; CELL FUNCTION; CELL MIGRATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SUMOYLATION;

AMINO ACID MOTIFS; BINDING SITES; CELL LINE; HERPESVIRUS 4, HUMAN; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNOPRECIPITATION; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; UBIQUITIN-CONJUGATING ENZYMES; VIRAL MATRIX PROTEINS; VIRUS LATENCY;

HUMAN HERPESVIRUS 4;

EID: 80054006064     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.05035-11     Document Type: Article

References (51)

1. Adamson, A. L., and S. Kenney. 2001. Epstein-Barr virus immediate-early protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodies. J. Virol. 75:2388-2399.
2. Albuquerque, M. L., C. M. Waters, U. Savla, H. W. Schnaper, and A. S. Flozak. 2000. Shear stress enhances human endothelial cell wound closure in vitro. Am. J. Physiol. Heart Circ. Physiol. 279:H293-H302.
3. Aviel, S., G. Winberg, M. Massucci, and A. Ciechanover. 2000. Degradation of the Epstein-Barr virus latent membrane protein 1 (LMP1) by the ubiquitin-proteasome pathway. Targeting via ubiquitination of the N-terminal residue. J. Biol. Chem. 275:23491-23499.
4. Bentz, G. L., and A. D. Yurochko. 2008. Human CMV infection of endothelial cells induces an angiogenic response through viral binding to EGF receptor and β1 and β3 integrins. Proc. Natl. Acad. Sci. U. S. A. 105:5531-5536.
5. Brennan, P., J. E. Floettmann, A. Mehl, M. Jones, and M. Rowe. 2001. Mechanism of action of a novel latent membrane protein-1 dominant negative. J. Biol. Chem. 276:1195-1203.
6. Dawson, C. W., L. Laverick, M. A. Morris, G. Tramoutanis, and L. S. Young. 2008. Epstein-Barr virus-encoded LMP1 regulates epithelial cell motility and invasion via the ERK-MAPK pathway. J. Virol. 82:3654-3664.
7. Dirmeier, U., et al. 2003. Latent membrane protein 1 is critical for efficient growth transformation of human B cells by Epstein-Barr virus. Cancer Res. 63:2982-2989.
8. Duan, X., J. O. Trent, and H. Ye. 2009. Targeting the SUMO E2 conjugating enzyme Ubc9 interaction for anti-cancer drug design. Anticancer Agents Med. Chem. 9:51-54.
9. Fan, Z., et al. 2006. SARS-CoV nucleocapsid protein binds to hUbc9, a ubiquitin conjugating enzyme of the sumoylation system. J. Med. Virol. 78:1365-1373.
10. Giorgino, F., et al. 2000. The sentrin-conjugating enzyme mUbc9 interacts with GLUT4 and GLUT1 glucose transporters and regulates transporter levels in skeletal muscle cells. Proc. Natl. Acad. Sci. U. S. A. 97:1125-1130.
11. Gires, O., et al. 1999. Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins. EMBO J. 18:3064-3073.
12. Guo, B., S. H. Yang, J. Witty, and A. D. Sharrocks. 2007. Signalling pathways and the regulation of SUMO modification. Biochem. Soc. Trans. 35:1414-1418.
13. Higuchi, M., E. Kieff, and K. M. Izumi. 2002. The Epstein-Barr virus latent membrane protein 1 putative Janus kinase 3 (JAK3) binding domain does not mediate JAK3 association or activation in B-lymphoma or lymphoblastoid cell lines. J. Virol. 76:455-459.
14. Hille, A., A. Badu-Antwi, D. Holzer, and F. A. Grasser. 2002. Lysine residues of Epstein-Barr virus-encoded nuclear antigen 2 do not confer secondary modifications via ubiquitin or SUMO-like proteins but modulate transcriptional activation. J. Gen. Virol. 83:1037-1042.
15. Huye, L. E., S. Ning, M. Kelliher, and J. S. Pagano. 2007. Interferon regulatory factor 7 is activated by a viral oncoprotein through RIP-dependent ubiquitination. Mol. Cell. Biol. 27:2910-2918.
16. Imai, S., J. Nishikawa, and K. Takada. 1998. Cell-to-cell contact as an efficient mode of Epstein-Barr virus infection of diverse human epithelial cells. J. Virol. 72:4371-4378.
17. Izumi, K. M., et al. 1999. The residues between the two transformation effector sites of Epstein-Barr virus latent membrane protein 1 are not critical for B-lymphocyte growth transformation. J. Virol. 73:9908-9916.
18. Kaul, S., J. A. Blackford, Jr., S. Cho, and S. S. Simons, Jr. 2002. Ubc9 is a novel modulator of the induction properties of glucocorticoid receptors. J. Biol. Chem. 277:12541-12549.
19. Kerscher, O. 2007. SUMO junction-what's your function? New insights through SUMO-interacting motifs. EMBO Rep. 8:550-555.
20. Kerscher, O., R. Felberbaum, and M. Hochstrasser. 2006. Modification of proteins by ubiquitin and ubiquitin-like proteins. Annu. Rev. Cell Dev. Biol. 22:159-180.
21. Kieser, A. 2008. 13th Bienn. Conf. Int. Assoc. Res. Epstein-Barr Virus Assoc. Dis., Guangzhou, China, abstr. 27. International Association for Research on Epstein-Barr Virus and Associated Diseases, Houston, TX.
22. Kroetz, M. B. 2005. SUMO: a ubiquitin-like protein modifier. Yale J. Biol. Med. 78:197-201.
23. Kurihara, I., et al. 2005. Ubc9 and protein inhibitor of activated STAT 1 activate chicken ovalbumin upstream promoter-transcription factor I-mediated human CYP11B2 gene transcription. J. Biol. Chem. 280:6721-6730.
24. Kurtzman, A. L., and N. Schechter. 2001. Ubc9 interacts with a nuclear localization signal and mediates nuclear localization of the paired-like homeobox protein Vsx-1 independent of SUMO-1 modification. Proc. Natl. Acad. Sci. U. S. A. 98:5602-5607.
25. Lang, V., and M. S. Rodriguez. 2008. Innate link between NF-κB activity and ubiquitin-like modifiers. Biochem. Soc. Trans. 36:853-857.
26. Li, H. P., and Y. S. Chang. 2003. Epstein-Barr virus latent membrane protein 1: structure and functions. J. Biomed. Sci. 10:490-504.
27. Lin, J., E. Johannsen, E. Robertson, and E. Kieff. 2002. Epstein-Barr virus nuclear antigen 3C putative repression domain mediates coactivation of the LMP1 promoter with EBNA-2. J. Virol. 76:232-242.
28. Luftig, M., et al. 2003. Epstein-Barr virus latent membrane protein 1 activation of NF-κB through IRAK1 and TRAF6. Proc. Natl. Acad. Sci. U. S. A. 100:15595-15600.
29. Mabb, A. M., and S. Miyamoto. 2007. SUMO and NF-κB ties. Cell. Mol. Life Sci. 64:1979-1996.
30. Maul, G. G., D. Negorev, P. Bell, and A. M. Ishov. 2000. Review: properties and assembly mechanisms of ND10, PML bodies, or PODs. J. Struct. Biol. 129:278-287.
31. Miller, W. E., G. Mosialos, E. Kieff, and N. Raab-Traub. 1997. Epstein-Barr virus LMP1 induction of the epidermal growth factor receptor is mediated through a TRAF signaling pathway distinct from NF-κB activation. J. Virol. 71:586-594.
32. Mo, Y. Y., and S. J. Moschos. 2005. Targeting Ubc9 for cancer therapy. Expert Opin. Ther. Targets 9:1203-1216.
33. Mo, Y. Y., Y. Yu, Z. Shen, and W. T. Beck. 2002. Nucleolar delocalization of human topoisomerase I in response to topotecan correlates with sumoylation of the protein. J. Biol. Chem. 277:2958-2964.
34. Muller, S., M. J. Matunis, and A. Dejean. 1998. Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. EMBO J. 17:61-70.
35. Ning, S., A. D. Campos, B. G. Darnay, G. L. Bentz, and J. S. Pagano. 2008. TRAF6 and the three C-terminal lysine sites on IRF7 are required for its ubiquitination-mediated activation by the tumor necrosis factor receptor family member latent membrane protein 1. Mol. Cell. Biol. 28:6536-6546.
36. Pagano, J. S. 2009. EBV diseases, p. 217-240. In B. Damania and J. M. Pipas (ed.), DNA tumor viruses. Springer Science and Business Media, New York, NY.
37. Rosendorff, A., et al. 2004. EBNA3C coactivation with EBNA2 requires a SUMO homology domain. J. Virol. 78:367-377.
38. Rui, H. L., et al. 2002. SUMO-1 modification of the C-terminal KVEKVD of Axin is required for JNK activation but has no effect on Wnt signaling. J. Biol. Chem. 277:42981-42986.
39. Schultheiss, U., et al. 2001. TRAF6 is a critical mediator of signal transduction by the viral oncogene latent membrane protein 1. EMBO J. 20:5678-5691.
40. Shair, K. H., C. I. Schnegg, and N. Raab-Traub. 2008. EBV latent membrane protein 1 effects on plakoglobin, cell growth, and migration. Cancer Res. 68:6997-7005.
41. Shimizu, N., H. Yoshiyama, and K. Takada. 1996. Clonal propagation of Epstein-Barr virus (EBV) recombinants in EBV-negative Akata cells. J. Virol. 70:7260-7263.
42. Sides, M. D., et al. 2011. Arsenic mediated disruption of promyelocytic leukemia protein nuclear bodies induces ganciclovir susceptibility in Epstein-Barr positive epithelial cells. Virology 416:86-97.
43. Song, J., L. K. Durrin, T. A. Wilkinson, T. G. Krontiris, and Y. Chen. 2004. Identification of a SUMO-binding motif that recognizes SUMO-modified proteins. Proc. Natl. Acad. Sci. U. S. A. 101:14373-14348.
44. Stewart, M. J., K. Smoak, M. A. Blum, and B. Sherry. 2005. Basal and reovirus-induced beta interferon (IFN-beta) and IFN-beta-stimulated gene expression are cell type specific in the cardiac protective response. J. Virol. 79:2979-2987.
45. Ungureanu, D., S. Vanhatupa, J. Gronholm, J. J. Palvimo, and O. Silvennoinen. 2005. SUMO-1 conjugation selectively modulates STAT1-mediated gene responses. Blood 106:224-226.
46. Vanhatupa, S., D. Ungureanu, M. Paakkunainen, and O. Silvennoinen. 2008. MAPK-induced Ser727 phosphorylation promotes SUMOylation of STAT1. Biochem. J. 409:179-185.
47. Wakisaka, N., et al. 2004. Epstein-Barr virus latent membrane protein 1 induces synthesis of hypoxia-inducible factor 1 alpha. Mol. Cell. Biol. 24: 5223-5234.
48. Yasugi, T., and P. M. Howley. 1996. Identification of the structural and functional human homolog of the yeast ubiquitin conjugating enzyme UBC9. Nucleic Acids Res. 24:2005-2010.
49. Zhang, Z., Q. Zhang, Y. Yu, Y. Ouyang, and Z. He. 2008. Construction and function analysis of the Epstein-Barr virus-encoded latent membrane protein-1 of CTAR3 region. Wei Sheng Wu Xue Bao 48:1308-1313. (In Chinese.)
50. Zhong, S., et al. 2000. Role of SUMO-1-modified PML in nuclear body formation. Blood 95:2748-2752.
51. Zimnik, S., M. Gaestel, and R. Niedenthal. 2009. Mutually exclusive STAT1 modifications identified by Ubc9/substrate dimerization-dependent SUMOylation. Nucleic Acids Res. 37:e30.